<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24236" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Lewy Body Dementia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Haider</surname>
            <given-names>Ali</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Spurling</surname>
            <given-names>Benjamin C.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>S&#x000e1;nchez-Manso</surname>
            <given-names>Juan Carlos</given-names>
          </name>
          <aff>Hospital Nuestra Se&#x000f1;ora del Rosario</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ali Haider declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Benjamin Spurling declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Juan Carlos S&#x000e1;nchez-Manso declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24236.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Lewy Body Dementia (LBD) encompasses two clinical entities: dementia with Lewy bodies and Parkinson disease dementia. It is a progressive degenerative brain disorder characterized by dementia, psychosis, and features of parkinsonism. Symptoms fluctuate with time and vary among different individuals. Diagnosis of LBD requires thorough clinical examination, as many of its features overlap with other dementia disorders. This activity reviews the cause and presentation of Lewy body dementia and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the histopathology of Lewy body dementia.</p></list-item><list-item><p>Assess&#x000a0;the presentation of a patient with Lewy body dementia.</p></list-item><list-item><p>Evaluate&#x000a0;the treatment for Lewy body dementia.</p></list-item><list-item><p>Communicate&#x000a0;the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by Lewy body dementia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24236&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24236">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24236.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Lewy Body Dementia (LBD) encompasses&#x000a0;2 clinical entities, namely dementia with Lewy bodies and Parkinson disease dementia. It is a progressive degenerative brain disorder characterized by dementia, psychosis, and features of parkinsonism. Symptoms fluctuate with time and vary among different individuals. Diagnosis of LBD requires thorough clinical examination as many of its features overlap with other dementia disorders. It is the third most common type of dementia after Alzheimer disease and Vascular dementia. It is characterized by the deposition of Lewy bodies in the&#x000a0;brain, which are intraneuronal cytoplasmic inclusion bodies with alpha-synuclein and ubiquitin aggregates.<xref ref-type="bibr" rid="article-24236.r1">[1]</xref><xref ref-type="bibr" rid="article-24236.r2">[2]</xref><xref ref-type="bibr" rid="article-24236.r3">[3]</xref></p>
        <p>There continues to be a debate&#x000a0;about the relationship between Parkinson disease and LBD. The latest LBD consortium has set an arbitrary 12-month rule to differentiate LBD from Parkinson disease with dementia. If the patient has Parkinson disease for 12 months or longer before any cognitive impairment is noticed, then the disorder is most likely Parkinson disease with dementia, if the time period is shorter then the disorder is LBD. In most cases of LBD, dementia precedes motor signs, particularly episodes of diminished responsiveness and visual hallucinations.</p>
      </sec>
      <sec id="article-24236.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of LBD is still unknown; however, genetics, environmental factors, and changes linked to aging may have a role and still require further research.</p>
      </sec>
      <sec id="article-24236.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>LBD is an under-diagnosed condition as it is poorly understood, and its clinical features overlap with other more common disorders, like Parkinson disease and Alzheimer disease.<xref ref-type="bibr" rid="article-24236.r4">[4]</xref>Studies have shown, however, that it accounts for up to 20% to 30% of all dementia cases. It is more common in men, and the incidence increases with age. It is prevalent in Asian, African, and European races. A family history of LBD and Parkinson disease increases a patient's risk.</p>
      </sec>
      <sec id="article-24236.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Like Alzheimer disease, LBD presents with acetylcholine deficiency, but it is more pronounced in LBD. Decreased levels of acetylcholine in the temporal and parietal cortex result in visual hallucinations (a prominent feature of LBD), while up-regulation of muscarinic M1 receptors in the temporal lobe results&#x000a0;in delusions. Dopamine levels also diminish. Postmortem examinations have revealed that LBD affects the substantia nigra, dorsal raphe, locus ceruleus, and the dorsal motor nucleus of the vagus nerve. The key feature of LBD is the presence of alpha-synuclein, a presynaptic protein whose function remains debatable. Other findings include the presence of ubiquitin and neurofilament proteins. Unlike Parkinson disease, the reduction in acetylcholine is much more severe in LBD. Using SPECT scans, patients with LBD may develop visual hallucinations (due to hypoperfusion of the occipital and parietal cortex), delusions (due to hyperperfusion of the frontal cortex), and misidentification (related to hypoperfusion of the limbic/paralimbic pathways.</p>
      </sec>
      <sec id="article-24236.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The pathology of LBD overlaps that of Parkinson disease and Alzheimer disease. Neuronal cytoplasmic inclusion bodies, called Lewy bodies (comprising aggregates of ubiquitin and alpha-synuclein) and found within the brain parenchyma (mainly in the brainstem, limbic system, and cerebral cortex), are characteristic of LBD.<xref ref-type="bibr" rid="article-24236.r5">[5]</xref><xref ref-type="bibr" rid="article-24236.r6">[6]</xref><xref ref-type="bibr" rid="article-24236.r7">[7]</xref>Genetic mutations, environmental toxins, and the aging process can lead to alpha-synuclein misfolding and its accumulation in Lewy bodies via oxidative stress and mitochondrial dysfunction. The location of Lewy bodies determines the clinical presentation. If Lewy bodies develop initially in the brainstem and cerebral cortex, then dementia sets on early, and we call it dementia with Lewy bodies; however, if Lewy bodies develop initially in the brain stem only and extend to the cerebral cortex later, then dementia occurs late in the disease process, and we call it Parkinson disease dementia. Other features include Lewy neuritis, senile plaques, neurofibrillary tangles, and neuronal loss in the substantia nigra, locus coeruleus, and Meynert nucleus.</p>
      </sec>
      <sec id="article-24236.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A large variation in symptoms manifested among patients and their onset time. The main features include progressive dementia (mainly affects attention and executive function; memory&#x000a0;loss is not common but can occur later in the disease process), fluctuation in cognitive function (with variation in attention and episodes of drowsiness), visual hallucinations (detailed and recurrent), delusions, syncope and features of parkinsonism like muscular rigidity, tremors, and bradykinesia.<xref ref-type="bibr" rid="article-24236.r3">[3]</xref><xref ref-type="bibr" rid="article-24236.r8">[8]</xref><xref ref-type="bibr" rid="article-24236.r9">[9]</xref><xref ref-type="bibr" rid="article-24236.r10">[10]</xref>&#x000a0;Other less common features include REM sleep behavior disorder, autonomic dysfunction, unexplained falls, depression, and sensitivity to antipsychotic medication.</p>
        <p>
<bold>Diagnostic Criteria</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Probable LBD:&#x000a0;progressive dementia&#x000a0;+ 2 main features.</p>
          </list-item>
          <list-item>
            <p>Possible LBD:&#x000a0;progressive dementia&#x000a0;+ 1 main feature.</p>
          </list-item>
        </list>
        <p>
<bold>Types</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Dementia with Lewy Bodies:&#x000a0;dementia occurring first or within&#x000a0;1 year of movement disorder.</p>
          </list-item>
          <list-item>
            <p>Parkinson Disease Dementia: dementia occurs in a patient who receives a diagnosis of Parkinson disease and then develops dementia symptoms after&#x000a0;1 year or more of the diagnosis.</p>
          </list-item>
        </list>
        <p>The Mini-Mental Status Exam reveals impairment in cognition in patients with LBD. However, because of patient symptom fluctuations, the test results may vary. The patient may often have some features of Parkinson disease, but the symptoms are often mild. One feature of LBD is the presence of orthostatic hypotension, which is often seen early in the disease.&#x000a0;Other features that should be screened include&#x000a0;hypersomnia, hyposmia, apathy, and anxiety.</p>
      </sec>
      <sec id="article-24236.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>No precise test can accurately diagnose LBD. Usually, a thorough workup,&#x000a0;including the following,&#x000a0;is useful to reach an alternative working diagnosis or rule out similar conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p>Detailed history and examination</p>
          </list-item>
          <list-item>
            <p>Assessment of mental function</p>
          </list-item>
          <list-item>
            <p>Blood tests (eg, vitamin B12 levels, chemistry panel, thyroid profile, syphilis, HIV)&#x000a0;to rule out other causes of dementia&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Imaging studies (eg, CT scan, MRI scan, SPECT scan, PET scan)</p>
          </list-item>
          <list-item>
            <p>Cerebrospinal fluid examinations have&#x000a0;no significant role when conducted in these patients</p>
          </list-item>
          <list-item>
            <p>Sleep evaluation for REM sleep behavior disorder</p>
          </list-item>
        </list>
        <p>Imaging studies are not helpful because the changes in the brain often mimic those seen in patients with vascular dementia. The Lewy body composite risk score was developed to assess LBD patients. The checklist covers 10 questions about motor, balance, stiffness, and non-motor symptoms. Due to the incomplete specificity in the clinical diagnosis and the pathological definition of the disease, a postmortem biopsy or autopsy is the only method to secure a definite diagnosis.</p>
      </sec>
      <sec id="article-24236.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Pharmacological Management</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Cholinesterase inhibitors: Used to treat the cognitive symptoms of LBD and are the mainstay of treatment. Initially developed for Alzheimer disease treatment, they are probably more effective in patients with LBD. These include rivastigmine, galantamine, and donepezil.</p>
          </list-item>
          <list-item>
            <p>Carbidopa-Levodopa: Used to treat movement symptoms; however, it has serious side effects and can lead to delusions, hallucinations, and confusion. Practitioners should use them with caution in these patients, and they should start with low doses if required.</p>
          </list-item>
          <list-item>
            <p>Atypical antipsychotics: Used to treat hallucinations that cause significant distress in patients not responding to standard cholinesterase inhibitors. Commonly used drugs include pimavanserin, clozapine, quetiapine,&#x000a0;and aripiprazole. Use with caution due to neuroleptic sensitivity in these patients.</p>
          </list-item>
          <list-item>
            <p>Clonazepam/melatonin: Used for REM sleep behavior disorder.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>SSRIs: Depression is common in patients with LBD and often requires antidepressant therapy with SSRIs.</p>
          </list-item>
          <list-item>
            <p>Memantine has been investigated in clinical trials and may work in patients with early disease.</p>
          </list-item>
        </list>
        <p>
<bold>Support and Therapies</bold>
</p>
        <p>Patient and caregiver education regarding disease symptoms and their management is necessary. Understanding the disease&#x000a0;helps the caregivers cope with everyday challenges. They require home modifications occasionally, and individual patient&#x000a0;needs should specifically guide them.<xref ref-type="bibr" rid="article-24236.r11">[11]</xref><xref ref-type="bibr" rid="article-24236.r12">[12]</xref><xref ref-type="bibr" rid="article-24236.r13">[13]</xref>&#x000a0;Patients can take part in different therapies to improve their quality of life, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Physical therapy</p>
          </list-item>
          <list-item>
            <p>Occupational therapy</p>
          </list-item>
          <list-item>
            <p>Speech therapy</p>
          </list-item>
          <list-item>
            <p>Support groups</p>
          </list-item>
          <list-item>
            <p>Individual and family psychotherapies.</p>
          </list-item>
          <list-item>
            <p>Exercise</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24236.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>It is important to differentiate LBD from similar conditions since it is more responsive to certain medications if used early in the disease course. Similar conditions include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Parkinson disease</p>
          </list-item>
          <list-item>
            <p>Alzheimer disease</p>
          </list-item>
          <list-item>
            <p>Frontotemporal dementia</p>
          </list-item>
          <list-item>
            <p>Prion-related diseases</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24236.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of LBD is fair to poor. Patients die from multiple complications like falls, immobility, cardiac complications, medication side effects, pneumonia, swallowing problems, and depression leading to suicide. The average life expectancy is only&#x000a0;5 to&#x000a0;8 years after the initial diagnosis. This also can be due to a lack of knowledge regarding LBD among physicians and the population and difficulty in differentiating it from other similar conditions, which leads to a delay in diagnosis, which delays the onset of specific therapy. Health professionals need to improve awareness regarding LBD and develop investigative methods to ensure its early diagnosis.</p>
      </sec>
      <sec id="article-24236.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Diagnosing and managing patients with LBD is extremely difficult and requires an interprofessional team that includes the primary care provider, psychiatrist, neurologist, radiologist, behavior specialist, internist, and specialty-trained nurses. Once the diagnosis is made, there is no effective treatment, and the condition progresses. All the available pharmacological agents are only used to treat behavioral symptoms. Home care nurses are vital in regularly assessing patients and providing support services. The education of the caregiver is vital. The family needs to be aware of the behavior changes, hallucinations, and fluctuations in cognition. Caregivers have to monitor the patient closely as their level of function is minimal. Most are not able to perform daily living activities and are prone to falls and aspiration pneumonia. Finally, the pharmacist should educate caregivers that there is no medical therapy to reverse the cognitive changes, and drugs that are used to manage behavior and motor deficits also have many adverse effects. Finally, a mental health nurse should follow these patients, as depression is common. Close communication between members of the interprofessional team is vital to improve outcomes.</p>
        <p>
<bold>Support and Therapies</bold>
</p>
        <p>Patient and caregiver education regarding symptoms of a disease and their management is necessary. Understanding the disease&#x000a0;helps the caregivers cope with everyday&#x000a0;challenges. They require home modifications occasionally, and individual patient&#x000a0;needs should specifically guide them. The outcomes for most patients are guarded, and the quality of life is poor.&#x000a0;Most patients eventually end up in a long-term care facility, where optimal treatment for basic living activities is not always provided.<xref ref-type="bibr" rid="article-24236.r14">[14]</xref><xref ref-type="bibr" rid="article-24236.r15">[15]</xref><xref ref-type="bibr" rid="article-24236.r16">[16]</xref></p>
      </sec>
      <sec id="article-24236.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24236&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24236">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/neurology/lewy-body-dementia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=24236">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24236/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24236">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24236.s14">
        <title>References</title>
        <ref id="article-24236.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>King</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Donaghy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barnett</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Martin-Ruiz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Peripheral inflammation in mild cognitive impairment with possible and probable Lewy body disease and Alzheimer's disease.</article-title>
            <source>Int Psychogeriatr</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>551</fpage>
            <page-range>551-560</page-range>
            <pub-id pub-id-type="pmid">30854988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24236.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Londos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hansson</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ros&#x000e9;n</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Englund</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Extreme sleep pattern in Lewy body dementia: a hypothalamic matter?</article-title>
            <source>BMJ Case Rep</source>
            <year>2019</year>
            <month>Mar</month>
            <day>09</day>
            <volume>12</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">30852516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24236.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chin</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Teodorczuk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Dementia with Lewy bodies: Challenges in the diagnosis and management.</article-title>
            <source>Aust N Z J Psychiatry</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>53</volume>
            <issue>4</issue>
            <fpage>291</fpage>
            <page-range>291-303</page-range>
            <pub-id pub-id-type="pmid">30848660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24236.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brenowitz</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Keene</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Hawes</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Hubbard</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Longstreth</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Woltjer</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Crane</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Kukull</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Alzheimer's disease neuropathologic change, Lewy body disease, and vascular brain injury in clinic- and community-based samples.</article-title>
            <source>Neurobiol Aging</source>
            <year>2017</year>
            <month>May</month>
            <volume>53</volume>
            <fpage>83</fpage>
            <page-range>83-92</page-range>
            <pub-id pub-id-type="pmid">28236716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24236.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Kordich</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cole-Strauss</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Labrie</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Parkinson's disease-linked <italic>D620N VPS35</italic> knockin mice manifest tau neuropathology and dopaminergic neurodegeneration.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2019</year>
            <month>Mar</month>
            <day>19</day>
            <volume>116</volume>
            <issue>12</issue>
            <fpage>5765</fpage>
            <page-range>5765-5774</page-range>
            <pub-id pub-id-type="pmid">30842285</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24236.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Truong</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Diffuse Lewy body disease.</article-title>
            <source>J Neurol Sci</source>
            <year>2019</year>
            <month>Apr</month>
            <day>15</day>
            <volume>399</volume>
            <fpage>144</fpage>
            <page-range>144-150</page-range>
            <pub-id pub-id-type="pmid">30807982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24236.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kasanuki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Koga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Iseki</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ichimiya</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Arai</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Mixed Alzheimer's and Lewy-related Pathology Can Cause Corticobasal Syndrome with Visual Hallucinations.</article-title>
            <source>Intern Med</source>
            <year>2019</year>
            <month>Jun</month>
            <day>15</day>
            <volume>58</volume>
            <issue>12</issue>
            <fpage>1813</fpage>
            <pub-id pub-id-type="pmid">30799336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24236.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hofmann</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wille</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kaminsky</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>[Guideline-conform exact diagnosis and coding of dementia].</article-title>
            <source>Z Gerontol Geriatr</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>52</volume>
            <issue>2</issue>
            <fpage>179</fpage>
            <page-range>179-194</page-range>
            <pub-id pub-id-type="pmid">30830315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24236.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Rocha Cabrero</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>EH</given-names>
              </name>
            </person-group>
            <chapter-title>Lewy Bodies</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">30725641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24236.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Durcan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Donaghy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Osborne</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Imaging in prodromal dementia with Lewy bodies: Where do we stand?</article-title>
            <source>Int J Geriatr Psychiatry</source>
            <year>2019</year>
            <month>May</month>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>635</fpage>
            <page-range>635-646</page-range>
            <pub-id pub-id-type="pmid">30714199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24236.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armstrong</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Lewy Body Dementias.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>128</fpage>
            <page-range>128-146</page-range>
            <pub-id pub-id-type="pmid">30707190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24236.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yilmaz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Spudich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Blennow</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zetterberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gissl&#x000e9;n</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders.</article-title>
            <source>Curr HIV/AIDS Rep</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>76</fpage>
            <page-range>76-81</page-range>
            <pub-id pub-id-type="pmid">30649659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24236.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Younce</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>A Systematic Review and Case Series of Ziprasidone for Psychosis in Parkinson's Disease.</article-title>
            <source>J Parkinsons Dis</source>
            <year>2019</year>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-71</page-range>
            <pub-id pub-id-type="pmid">30475775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24236.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armstrong</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Alliance</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Corsentino</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>DeKosky</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cause of Death and End-of-Life Experiences in Individuals with Dementia with Lewy Bodies.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>67</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <page-range>67-73</page-range>
            <pub-id pub-id-type="pmid">30291740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24236.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siderowf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aarsland</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mollenhauer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Ravina</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials.</article-title>
            <source>Mov Disord</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>528</fpage>
            <page-range>528-536</page-range>
            <pub-id pub-id-type="pmid">29624752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24236.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morrin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Servant</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Aarsland</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rajkumar</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Systematic review of the efficacy of non-pharmacological interventions in people with Lewy body dementia.</article-title>
            <source>Int Psychogeriatr</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>395</fpage>
            <page-range>395-407</page-range>
            <pub-id pub-id-type="pmid">28988547</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
